MRI-Guided radiation shows promise for brain tumors in new trial
NCT ID NCT07586657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve local control and reduce brain damage compared to standard methods. The study enrolls 200 patients with large or complex brain metastases who have not had prior brain radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adaptive radiotherapy (MR-guided)
What this could lead to
If successful, this could establish a new standard for treating large or complex brain metastases, offering better tumor control and fewer side effects than current methods.
What could go wrong
This is a single-arm phase 3 study without a control group, so results may be less definitive. The treatment is time-consuming (40-60 minutes per session) and may not be suitable for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.